Clinical Guidelines
From the Journals
AAO Updates HCQ Retinopathy Guidance
-
By
-
April 23, 2026
-
3 min
-
1
Low HCQ retinopathy risk with appropriate dosing.
-
2
Utilize OCT and FAF for screening.
-
3
Annual screening advised; can defer for low-risk patients.
-
4
Risk factors include dose, duration, and age.
-
5
Toxicity unlikely to progress after drug withdrawal in early stages.
-
6
New technologies like AI for imaging not fully validated yet.
-
7
Most patients can take HCQ for years with proper management.
-
8
Risk estimates depend on adherence to treatment guidelines.
